Related Experiment Videos
Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivo
A Thybusch-Bernhardt1, A Aigner, S Beckmann
1Department of Surgery, University Hospital Kiel, 24105 Kiel, Germany.
Abstract:
We have analysed HER-2 expression and function in pancreatic cancer cells to determine whether HER-2 has a rate-limiting role for pancreatic cancer cell growth in vitro and in vivo. To specifically assess HER-2 function, we used HER-2-targeted ribozymes expressed under the control of the tet-off promoter system. Six out of 11 human pancreatic cancer cell lines expressed all four epidermal growth factor (EGF)-receptor family members (HER-1 (EGF-R), HER-2, HER-3, and HER-4), including Panc89 cells. Expression of the ribozymes quenched endogenous HER-2 mRNA levels in Panc89 cells by approximately 40-60% which was reflected by a 40-50% reduction of the HER-2 surface glycoprotein. HER-2 depletion inhibited the in vitro proliferation rate by approximately 40% and decreased in vivo tumour growth by approximately 60% (P<0.05). Our study demonstrates for the first time a rate-limiting role for HER-2 in pancreatic cancer cell proliferation and suggests HER-2 targeting as a potential approach in pancreatic cancer therapy.
Insights
This study reveals that Human Epidermal growth factor Receptor 2 (HER-2) plays a critical role in pancreatic cancer growth. Inhibiting HER-2 significantly reduces both in vitro cell proliferation and in vivo tumor development.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Pancreatic cancer is an aggressive malignancy with limited treatment options.
- The role of Human Epidermal growth factor Receptor 2 (HER-2) in pancreatic cancer progression is not fully understood.
- Understanding HER-2's function is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of HER-2 in the growth of pancreatic cancer cells in vitro and in vivo.
- To determine if HER-2 acts as a rate-limiting factor for pancreatic cancer cell proliferation.
- To assess the therapeutic potential of targeting HER-2 in pancreatic cancer.
Main Methods:
- Analysis of HER-2 expression in 11 human pancreatic cancer cell lines.
- Utilized HER-2-targeted ribozymes under a tet-off promoter system to specifically inhibit HER-2 function.
- Quantified HER-2 mRNA and surface glycoprotein levels following ribozyme expression.
- Assessed the impact of HER-2 depletion on in vitro cell proliferation and in vivo tumor growth.
Main Results:
- Six out of 11 pancreatic cancer cell lines, including Panc89, expressed all four epidermal growth factor receptor family members.
- HER-2-targeted ribozymes reduced HER-2 mRNA by 40-60% and surface glycoprotein by 40-50% in Panc89 cells.
- HER-2 depletion resulted in a 40% decrease in in vitro proliferation and a 60% reduction in in vivo tumor growth (P<0.05).
Conclusions:
- This study provides the first evidence of a rate-limiting role for HER-2 in pancreatic cancer cell proliferation.
- Targeting HER-2 presents a promising therapeutic strategy for pancreatic cancer.
- Further research into HER-2-targeted therapies for pancreatic cancer is warranted.